ArticleNeurochemical research2025
Ferulago angulata Extract Protects against Beta-amyloid-induced Memory Impairment Through Modulation of Monoaminoxidase Enzymes in the Rat's Hippocampus.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferulago angulata, a medicinal plant of the Apiaceae family, is known for its antioxidative, anti-inflammatory, anti-apoptotic, and neuroprotective effects. This study investigated the protective potential of F. angulata total extract against memory impairment induced by amyloid β-peptide (Aβ25-35) in rats. Aβ25-35 was bilaterally administered into the CA1 region of the hippocampus in male Wistar rats for four consecutive days. Starting from the first surgery day, rats received oral treatment with F. angulata extract (400 mg/kg) or Rivastigmine (1.5 mg/kg) for 16 consecutive days. Morris water maze tests conducted from days 14 to 17 evaluated the learning and memory performance, followed by biochemical and molecular assays on isolated hippocampi. F. angulata extract significantly reversed Aβ-induced deficits in learning and memory. In the Aβ group, monoamine oxidase A and B enzyme activities and gene expression increased, along with elevated acetylcholinesterase gene expression but decreased enzyme activity compared to the control group. Treatment with F. angulata extract mitigated all these abnormalities. Safety assessments revealed no alterations in blood biochemistry or histology following F. angulata extract treatment. In conclusion, our findings suggest that F. angulata extract possesses neuroprotective properties, and ameliorates Aβ-induced memory deficits by modulating monoamine oxidase enzyme activity and acetylcholinesterase levels without significant adverse effects. Thus, this safe herbal extract shows promise for further exploration in Alzheimer's disease research and potential therapeutic interventions.
Indexed as
Identifiers
40042687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.